Rosuvastatin 10 mg (n = 504) | Atorvastatin 20 mg (n = 492) | |
---|---|---|
Mean age, years (SD) | 60.2 (10.4) | 60.7 (10.6) |
Male gender, n (%) | 273 (54.2) | 285 (57.9) |
Mean BMI, kg/m2 (SD) | 29.7 (5.6) | 29.7 (5.9) |
Race, n (%) | ||
Caucasian | 376 (74.6) | 380 (77.2) |
Hispanic | 98 (19.4) | 90 (18.3) |
Black | 23 (4.6) | 17 (3.5) |
Asian | 6 (1.2) | 3 (0.6) |
Other | 1 (0.2) | 2 (0.4) |
Renal function*, n (%) | ||
Normal | 292 (57.9) | 271 (55.1) |
Mild impairment | 177 (35.1) | 190 (38.6) |
Moderate impairment | 35 (6.9) | 29 (5.9) |
Metabolic syndrome†, n (%) | 254 (50.4) | 237 (48.2) |
Diabetes (type 1 or 2), n (%) | 256 (50.8) | 250 (50.8) |
CHD or CHD-risk equivalents, n (%) | 431 (85.5) | 407 (82.7) |
Patients without CHD or a CHD-risk equivalent, n (%) | 72 (14.3) | 85 (17.3) |
Framingham 10-year risk > 20% | 30 (6.0) | 32 (6.5) |
Framingham 10-year risk ≥ 10% and ≤ 20% | 17 (3.4) | 25 (5.1) |
Framingham 10-year risk < 10% | 25 (5.0) | 28 (5.7) |